Co-Authors
This is a "connection" page, showing publications co-authored by Antonio Di Biagio and Giordano Madeddu.
Connection Strength
0.575
-
SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiol. 2019 Jul; 42(3):150-155.
Score: 0.208
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.179
-
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis. 2018 07 31; 18(1):357.
Score: 0.049
-
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infect Drug Resist. 2018; 11:615-623.
Score: 0.048
-
Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis. 2017; 4(4):ofx239.
Score: 0.046
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.045